Evidence map›Paper›PMID 41886743›Full record

ArticleJournal of medicinal chemistry2026

Discovery of the SARS-CoV-2 Papain-Like Protease Inhibitor MR1-114: From Structure-Based Design to

Malla Reddy Gannarapu, Divakar Indukuri, Cameron Holberg, Kiira Ratia, Omar Lozano Ramos, Savio Cardoza, Ganga Reddy Velma, Soumya Reddy Musku, Zuohuang Qi, Steve Slilaty and 4 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Malla Reddy GannarapuDepartment of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.
Divakar IndukuriDepartment of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.
Cameron HolbergDepartment of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.
Kiira RatiaResearch Resources Center, University of Illinois Chicago (UIC), Chicago, Illinois 60612, United States.
Omar Lozano RamosDepartment of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.ORCID 0000-0002-8966-6954
Savio CardozaDepartment of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.
Ganga Reddy VelmaDepartment of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.ORCID 0000-0001-5054-2519
Soumya Reddy MuskuDepartment of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.
Zuohuang QiDepartment of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.
Steve SlilatySunshine Biopharma Inc., 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, Florida 33301, United States.
Zuomei LiSunshine Biopharma Inc., 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, Florida 33301, United States.
Lijun RongDepartment of Microbiology, College of Medicine, University of Illinois (UIC), Chicago, Illinois 60612, United States.
Gregory R J ThatcherDepartment of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.
Rui XiongDepartment of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona 85721, United States.ORCID 0000-0002-6350-9037

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SARS-CoV-2 papain-like protease (PLpro) is a critical target for antiviral intervention. Here, we report the discovery of MR1-114 (compound

Indexed as

Antiviral AgentsCoronavirus Papain-Like ProteasesCOVID-19 Drug TreatmentProtease InhibitorsSARS-CoV-2AnimalsBiological AvailabilityDrug DesignDrug DiscoveryHumansMiceRatsStructure-Activity RelationshipVirus ReplicationAntiviral AgentsCoronavirus Papain-Like Proteasespapain-like protease, SARS-CoV-2Protease Inhibitors

Identifiers

PMID41886743
PMCPMC13071871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.